Novel ELISA system for detection of N‐ERC/mesothelin in the sera of mesothelioma patients

Abstract

We have developed a novel enzyme-linked immunosorbent assay (ELISA) system for the detection of N-ERC/mesothelin in the serum of mesothelioma patients and have begun to examine its clinical usefulness. N-ERC/mesothelin is a 31-kDa protein that forms the N-terminal fragment of the full-length 71-kDa ERC/ mesothelin protein, and is physiologically secreted into the blood of mesothelioma patients where it can be detected using our sandwich ELISA containing two antibodies (rabbit polyclonal anti-ERC/mesothelin antibody-282 and mouse monoclonal antibody 7E7). Our ELISA system has thus far detected much higher serum levels of N-ERC/mesothelin in mesothelioma patients than in healthy controls or patients with other lung or pleural diseases.

Clinical utility of diagnostic markers for malignant pleural mesothelioma

“…Two ELISA systems have been developed to date. The first one by Shiomi et al (and which is commercially available from Immuno-Biological Laboratories Gunma, Japan, under the name of N-ERC/mesothelin) was evaluated in a short series of fourteen patients with MPM which were compared with healthy controls, patients pleural metastases of lung adenocarcinomas and patients with benign pleural lesions [46]. A second test developed by Onda et al was used to evaluate 56 patients with MPM which were compared with normal controls [83].…”

“…Antibodies against mesothelin were generated [38, 44,45] and to date at least two ELISA assays are available, having the brand name of MESO-MARK™ by Fujirebio diagnostics (antibodies developed by Scholler et al [38]) and one by Immuno-Biological Laboratories under the name of C-ERC/Mesothelin with antibodies developed by Shiomi et al [46]. The data available for the second assay is limited and it is difficult to say if this assay is better than the Mesomark™ kit which has been used by the majority of investigators and showed a very good reproducibility and precision with little constraints concerning sample storage or interference with other substances [47][48][49].…”

Feasibility of large-scale screening using N-ERC/mesothelin levels in the blood for the early diagnosis of malignant mesothelioma

“…recently, soluble mesothelin-related protein (1) and serum mesothelin have been reported to be potentially useful markers for the early diagnosis of mm (2,3). a 71-kda precursor protein of human Erc/mesothelin can be cleaved into a 40-kda c-terminal fragment as a surface Gpi-anchored glycoprotein and a 31-kda n-terminal fragment as a secreted protein.…”

“…a 71-kda precursor protein of human Erc/mesothelin can be cleaved into a 40-kda c-terminal fragment as a surface Gpi-anchored glycoprotein and a 31-kda n-terminal fragment as a secreted protein. We focused on this n-Erc/ mesothelin, as it is physiologically secreted into the blood, and as a specific ELISA system has been developed for N-ERC/ mesothelin (2,3).…”

The utility of serum N-ERC/mesothelin as a biomarker of ovarian carcinoma

“…This protein is expressed on various malignant tumors, including mesothelioma and pulmonary, pancreatic and ovarian carcinomas. Recently, it has been recognized that the measurement of blood N-ERC/mesothelin levels aids early detection in and postoperative therapeutic monitoring of patients with mesothelioma, who have been exposed to asbestos (1)(2)(3).…”